Market Closed -
Nasdaq
21:30:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
2.93
USD
|
-3.62%
|
|
-16.29%
|
-12.54%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
74.72
|
103.9
|
74.5
|
28.54
|
8.191
|
Enterprise Value (EV)
1 |
53.74
|
95.26
|
20.54
|
15.16
|
0.6201
|
P/E ratio
|
-0.61
x
|
-1.2
x
|
-1.3
x
|
-0.65
x
|
-1.49
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16,577,637
x
|
45,262,757
x
|
18,899,815
x
|
17,563,618
x
|
-
|
EV / Revenue
|
16,577,632
x
|
45,262,754
x
|
18,899,802
x
|
17,563,610
x
|
-
|
EV / EBITDA
|
-0.62
x
|
-1.36
x
|
-1.38
x
|
-0.64
x
|
-0.85
x
|
EV / FCF
|
-1.07
x
|
-2.9
x
|
-3.67
x
|
-1.15
x
|
-0.86
x
|
FCF Yield
|
-93.1%
|
-34.5%
|
-27.3%
|
-86.9%
|
-116%
|
Price to Book
|
0.77
x
|
1.75
x
|
1.55
x
|
2.73
x
|
0.73
x
|
Nbr of stocks (in thousands)
|
1,373
|
1,698
|
2,166
|
2,175
|
2,445
|
Reference price
2 |
54.40
|
61.20
|
34.40
|
13.12
|
3.350
|
Announcement Date
|
12/03/20
|
25/02/21
|
24/02/22
|
22/03/23
|
05/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
4.507
|
2.296
|
3.942
|
1.625
|
-
|
EBITDA
1 |
-104.7
|
-119.8
|
-76.24
|
-53.84
|
-44.31
|
-9.582
|
EBIT
1 |
-106.2
|
-122.5
|
-78.53
|
-54.31
|
-44.37
|
-9.647
|
Operating Margin
|
-
|
-2,718.82%
|
-3,420.47%
|
-1,377.83%
|
-2,730.58%
|
-
|
Earnings before Tax (EBT)
1 |
-115.3
|
-123
|
-77.8
|
-51.65
|
-44.08
|
-12.59
|
Net income
1 |
-115.3
|
-123
|
-77.8
|
-51.65
|
-44.08
|
-5.263
|
Net margin
|
-
|
-2,729.27%
|
-3,388.59%
|
-1,310.17%
|
-2,712.49%
|
-
|
EPS
2 |
-148.2
|
-89.85
|
-51.18
|
-26.39
|
-20.28
|
-2.251
|
Free Cash Flow
1 |
-51.69
|
-69.58
|
-35.8
|
-20.33
|
-24.82
|
-9.518
|
FCF margin
|
-
|
-1,543.88%
|
-1,559.31%
|
-515.61%
|
-1,527.11%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/19
|
12/03/20
|
25/02/21
|
24/02/22
|
22/03/23
|
05/03/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
0.348
|
0.533
|
0.711
|
0.306
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.28
|
-14.34
|
-12.98
|
-13.43
|
-10.61
|
Operating Margin
|
-3,242.82%
|
-2,690.06%
|
-1,826.16%
|
-4,389.87%
|
-
|
Earnings before Tax (EBT)
1 |
-11.29
|
-10.78
|
-12.98
|
-13.39
|
-10.5
|
Net income
1 |
-11.29
|
-10.78
|
-12.98
|
-13.39
|
-10.5
|
Net margin
|
-3,244.25%
|
-2,021.58%
|
-1,825.32%
|
-4,375.16%
|
-
|
EPS
2 |
-5.200
|
-4.723
|
-6.000
|
-6.200
|
-4.800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
24/02/22
|
04/05/22
|
09/08/22
|
03/11/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
21
|
8.66
|
54
|
13.4
|
7.57
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.7
|
-69.6
|
-35.8
|
-20.3
|
-24.8
|
-9.52
|
ROE (net income / shareholders' equity)
|
1,212%
|
-282%
|
-99%
|
-95.9%
|
-150%
|
-116%
|
ROA (Net income/ Total Assets)
|
-1,032%
|
-79%
|
-32.5%
|
-38.9%
|
-71.7%
|
-38.3%
|
Assets
1 |
11.17
|
155.7
|
239.2
|
132.9
|
61.52
|
13.73
|
Book Value Per Share
2 |
-13.40
|
70.80
|
34.90
|
22.20
|
4.800
|
4.560
|
Cash Flow per Share
|
-
|
68.80
|
32.00
|
24.90
|
6.150
|
3.060
|
Capex
1 |
3.44
|
6.89
|
1.52
|
0.01
|
-
|
-
|
Capex / Sales
|
-
|
152.83%
|
66.38%
|
0.18%
|
-
|
-
|
Announcement Date
|
11/03/19
|
12/03/20
|
25/02/21
|
24/02/22
|
22/03/23
|
05/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -12.54% | 7.44M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|